SN

Swapan Nath

Active Director Director DIN 10384987
DIN 10384987 First appointment Nov 2023 Primary industry Paper
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2023
Shareholding value •••• Premium profile

About Swapan Nath

Data last updated:

Swapan Nath is a Director at Lupikem Pharmaceuticals Private Limited (since 2023). The company operates in Paper. Lupikem Pharmaceuticals Private Limited reported revenue of ₹3.3 Lakh (FY 2025).

DIN 10384987
Primary Designation Director
Industry Paper
First Appointment 07 Nov 2023
Oldest Company Age 3 yrs
Largest company Lupikem Pharmaceuticals Private Limited · ₹3.3 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director07 Nov 20232023₹3.3 Lakh (FY 2025)Active

Board colleagues of Swapan Nath

Directorship timeline

Open interactive timeline →
Lupikem Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Swapan Nath

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Swapan Nath

Swapan Nath currently holds 1 directorship: Lupikem Pharmaceuticals Private Limited (Director, since 07 Nov 2023, revenue ₹3.3 Lakh (FY 2025)).

Swapan Nath was first appointed on 07 Nov 2023 as Director at Lupikem Pharmaceuticals Private Limited.

The current boards of Swapan Nath's companies include Arjun Nath (Lupikem Pharmaceuticals Private Limited), Joyshree Deb Nath (Lupikem Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available